Insulin detemir


Generic Medicine Info
Administration
May be taken with or without food. For patients treated w/ once daily regimen, administer w/ evening meal or at bedtime. For patients who need twice daily dosing, the evening dose can be administered either w/ the evening meal or at bedtime or 12 hr after the morning dose.
Contraindications
Hypersensitivity. Episodes of hypoglycaemia.
Special Precautions
Patient with risk factors for hypoglycaemia, including changes in meal pattern, level of physical activity, concurrent illness or drugs used; cardiac disease, risk factors for developing heart failure and hypokalaemia (e.g. use of loop diuretics); adrenal, pituitary, or thyroid gland diseases; severe hypoalbuminaemia. Not recommended for use in patients with diabetic ketoacidosis. Not to be administered via IV, IM, or insulin infusion pumps. Renal and hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may impair the patient's ability to concentrate and react due to hypoglycaemia; if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood glucose (closely monitor in patients with renal or hepatic impairment); electrolytes; HbA1c (at least twice yearly in patients with stable glycaemic control; quarterly in patients not meeting treatment goals or treatment change); serum K in patients at risk of hypokalaemia; renal and hepatic function; weight.
Adverse Reactions
Significant: Hypoglycaemia, hypokalaemia; hyperglycaemia (inadequate dosing or treatment discontinuation in patients with type 1 cases); certain skin and SC tissue disorders (e.g. lipodystrophy, cutaneous amyloidosis), inj site reactions (e.g. redness, pain, inflammation, hives, bruising, swelling, itching). Eye disorders: Refraction disorders, diabetic retinopathy. Gastrointestinal disorders: Abdominal pain, gastroenteritis, nausea, vomiting. General disorders and administration site conditions: Influenza-like illness, fever, oedema. Infections and infestations: Viral infection. Musculoskeletal and connective tissue disorders: Back pain. Nervous system disorders: Headache. Rarely, peripheral neuropathy. Respiratory, thoracic and mediastinal disorders: Pharyngitis, cough, upper respiratory tract infection, bronchitis, rhinitis.
Potentially Fatal: Severe and prolonged episodes of hypoglycaemia resulting in unconsciousness, convulsion, or brain damage (temporary or permanent); untreated hypokalaemia leading to respiratory paralysis and ventricular arrhythmia; untreated hyperglycaemia leading to diabetic ketoacidosis (patients with type 1 cases); hypersensitivity reactions, including anaphylaxis.
Drug Interactions
May cause dose-related fluid retention and exacerbate heart failure with peroxisome proliferator-activated receptor (PPAR)-γ agonists, including thiazolidinediones (e.g. pioglitazone). May increase risk of hypoglycaemia with other antidiabetic agents, GLP-1 receptor agonists, ACE inhibitors, β-blockers, angiotensin II receptor blockers, MAOIs, fibrates, salicylates, and sulfonamides. Hypoglycaemic symptoms may be masked by β-blockers, clonidine, guanethidine, reserpine. May reduce hypoglycaemic effects with glucagon, corticosteroids, thyroid hormones, atypical antipsychotics, thiazide diuretics, sympathomimetic agents (e.g. salbutamol, epinephrine, terbutaline), oral contraceptives, and danazol.
ATC Classification
A10AE05 - insulin detemir ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by CIMS based on insulin detemir from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in